Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction

References

• Sullivan M, Levy WC, Russo JE, et al. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. J. Card. Fail. 2004;10:390–396.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Easton K, Coventry P, Lovell K, et al. Prevalence and measurement of anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs. 2016;31:367–379.
   PubMed Web of Science ®Google Scholar
• Smith L. Evaluation and treatment of depression in patients with heart failure. J Am Acad Nurse Pract. 2010;22:440–448.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespérance Fois, Habra Martine, et al. Clinical perspective. Circulation. 2009;120:134–140.
   PubMed Web of Science ®Google Scholar
• Sokoreli I, de Vries JJG, Pauws SC, et al. Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis. Heart Fail Rev. 2016;21:49–63.
   PubMed Web of Science ®Google Scholar
• Moser DK. The rust of life: impact of anxiety on cardiac patients. Am J Crit Care. 2007;16:361–369.
   PubMed Web of Science ®Google Scholar
• McMurray JV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, Document Reviewers, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10:e003430.
   PubMed Web of Science ®Google Scholar
• Martens P, Beliën H, Dupont M, et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435.
   PubMed Web of Science ®Google Scholar
• Malfatto G, Ravaro S, Caravita S, et al. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiol. [2019];[5 p.].
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio. 1996; 78:490–498.
   Google Scholar
• Wang YP, Gorenstein C. Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics. 2013;68:1274–1287.
   PubMed Web of Science ®Google Scholar
• Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897.
   PubMed Web of Science ®Google Scholar
• Kapci E, Uslu R, Turkcapar H, et al. Beck Depression Inventory II: evaluation of the psychometric properties and cut‐off points in a Turkish adult population. Depress Anxiety. 2008;25:E104–E110.
   PubMedGoogle Scholar
• Ulusoy M, Sahin NH, Erkmen H. The Beck anxiety inventory: psychometric properties. J Cogn Psychother. 1998;12:163–172.
   Google Scholar
• Rostagno C, Gensini GF. Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure. Intern Emerg Med. 2008;3:205–212.
   PubMed Web of Science ®Google Scholar
• Du H, Wonggom P, Tongpeth J, et al. Six-minute walk test for assessing physical functional capacity in chronic heart failure. Curr Heart Fail Rep. 2017;14:158–166.
   PubMedGoogle Scholar
• Bohannon RW, Crouch R. Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23:377–381.
   PubMed Web of Science ®Google Scholar
• Daskalopoulou M, George J, Walters K, et al. Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: data linkage study of 1.9 million women and men. PLoS One. 2016;11:e0153838.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol. 2017;2:536–546.
   PubMed Web of Science ®Google Scholar
• Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–1537.
   PubMed Web of Science ®Google Scholar
• Gathright EC, Goldstein CM, Josephson RA, et al. Depression increases the risk of mortality in patients with heart failure: a meta-analysis. J Psychosom Res. 2017; 94:82–89.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–1292.
   PubMed Web of Science ®Google Scholar
• Moullec G, Plourde A, Lavoie KL, et al. Beck Depression Inventory II: determination and comparison of its diagnostic accuracy in cardiac outpatients. Eur J Prev Cardiolog. 2015;22:665–672.
   PubMed Web of Science ®Google Scholar
• Mueller-Tasch T, Bernd L, Nicole L, et al. Anxiety and self-care behaviour in patients with chronic systolic heart failure: a multivariate model. Eur J Cardiovasc Nurs. 2018; 17:170–177.
   PubMed Web of Science ®Google Scholar
• Jaarsma T, Johansson P, Ågren S, et al. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Supportive Palliative Care. 2010;4:233–237.
   PubMedGoogle Scholar
• Carels RA. The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients. Qual Life Res. 2004;13:63–72.
   PubMed Web of Science ®Google Scholar
• Unemori E, Sam LT, Gad C, et al., inventors. Method of treating dyspnea associated with acute heart failure. 2013.
   Google Scholar
• Vitale G, Romano G, Di Franco A, et al. Early effects of sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. JCM. 2019;8:262.
   Web of Science ®Google Scholar
• Peschel T, Schönauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609–614.
   PubMed Web of Science ®Google Scholar
• Werdan K. The activated immune system in congestive heart failure–from dropsy to the cytokine paradigm. Journal Intern Med. 1998;243:87–92.
   Google Scholar
• Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009;71:171–186.
   PubMed Web of Science ®Google Scholar
• Xiong GL, Prybol K, Boyle SH, et al. Inflammation markers and major depressive disorder in patients with chronic heart failure: results from the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) study. Psychosom Med. 2015;77:808–815.
   PubMed Web of Science ®Google Scholar
• Jing W, Vaziri ND, Nunes A, et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Trans Res. 2017;9:5473–5484.
   PubMed Web of Science ®Google Scholar
• Suematsu Y, Jing W, Nunes A, et al. LCZ696 (Sacubitril/Valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Card Fail. 2018;24:266–275.
   PubMed Web of Science ®Google Scholar
• Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart. 2004;90:1248–1255.
   PubMed Web of Science ®Google Scholar
• Francis JL, Weinstein AA, Krantz DS, et al. Association between symptoms of depression and anxiety with heart rate variability in patients with implantable cardioverter defibrillators. Psychosom. Med. 2009;71:821–827.
   PubMed Web of Science ®Google Scholar
• Kawachi I, Sparrow D, Vokonas PS, et al. Decreased heart rate variability in men with phobic anxiety (data from the Normative Aging Study). Am J Cardiol. 1995;75:882–885.
   PubMed Web of Science ®Google Scholar
• Stein PK, Carney RM, Freedland KE, et al. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J. Psychosom. Res. 2000;48:493–500.
   PubMed Web of Science ®Google Scholar
• Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19:167–176.
   PubMed Web of Science ®Google Scholar
• Steer RA, Ranieri WF, Beck AT, et al. Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients. J Anxiety Disord. 1993;7:195–205.
   Web of Science ®Google Scholar
• Fraguas R, da Silva Telles RM, Alves T, et al. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Contemp Clin Trials. 2009;30:205–211.
   PubMed Web of Science ®Google Scholar
• Angermann CE, Gelbrich Götz, Störk Stefan, et al.; on behalf of the MOOD-HF Investigators. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re‐uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD‐HF. Eur J Heart Fail. 2007;9:1212–1222.
   PubMed Web of Science ®Google Scholar
• Angermann CE, Gelbrich G, Störk S, et al.; for the MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. 2016;315:2683–2693.
   PubMed Web of Science ®Google Scholar
• Flynn KE, Piña IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451–1459.
   PubMed Web of Science ®Google Scholar
• Yost G, Bhat G, Mahoney E, et al. Reduced anxiety and depression in patients with advanced heart failure after left ventricular assist device implantation. Psychosomatics. 2017;58:406–414.
   PubMed Web of Science ®Google Scholar